Intra-Cellular Therapies, Inc. Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc.

ITCI

Rang in aandelen #1690
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Aandeelprijs
$131.87
Laatst gesynchroniseerd: 2025-04-02
Marktkapitalisatie
$12.68B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Intra-Cellular Therapies, Inc. (ITCI)

Categorie

Healthcare
Aandelsplitsingen voor Intra-Cellular Therapies, Inc. (ITCI)
Het aandeel Intra-Cellular Therapies, Inc. (symbool: ITCI) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Oct 20, 2026.
Eén aandeel ITCI dat vóór Oct 20, 2026 werd gekocht, staat nu gelijk aan 0 aandelen ITCI.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten